


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:17Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405125" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405125</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405125</article-id><article-id pub-id-type="pmcid-ver">PMC12405125.1</article-id><article-id pub-id-type="pmcaid">12405125</article-id><article-id pub-id-type="pmcaiid">12405125</article-id><article-id pub-id-type="pmid">40892159</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03533-9</article-id><article-id pub-id-type="publisher-id">3533</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Analysis</subject></subj-group></article-categories><title-group><article-title>Mendelian randomization analysis reveals causal roles of inflammatory cytokines in thyroid cancer pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="B">Bo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="T">Tingting</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="J">Jihua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bi</surname><given-names initials="W">Wen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nie</surname><given-names initials="C">Chunlei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jiewu</given-names></name><address><email>zhang_jwu_nic@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01f77gp95</institution-id><institution-id institution-id-type="GRID">grid.412651.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 3502</institution-id><institution>Department of Head and Neck Surgery, </institution><institution>Harbin Medical University Cancer Hospital, </institution></institution-wrap>No.150 Haping Road, Nangang District, Harbin, 150081 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05jscf583</institution-id><institution-id institution-id-type="GRID">grid.410736.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2204 9268</institution-id><institution>Psychology and Health Management Centre, </institution><institution>Harbin Medical University, </institution></institution-wrap>No.157, Baojian Road, Nangang District, Harbin, 150076 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1671</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3533.pdf"/><abstract id="Abs1"><p id="Par1">Thyroid cancer is a common endocrine malignancy associated with various inflammatory factors. This research aimed to explore the causal relationships between 41 inflammatory factors and the risk of thyroid cancer using Mendelian randomisation (MR) analysis. MR analysis was performed using genetic data from two publicly available European genome-wide association studies (GWAS). Instrumental variables were selected based on single-nucleotide polymorphisms significantly associated with cytokine levels. Causal relationships were assessed using the inverse variance weighted method, with sensitivity analyses to evaluate heterogeneity and pleiotropy. The results suggest that interleukin-1 receptor antagonist (<italic toggle="yes">IL-1RA</italic>) and &#946;-nerve growth factor (<italic toggle="yes">B-NGF</italic>) are risk factors for thyroid cancer, while macrophage colony-stimulating factor (<italic toggle="yes">M-CSF</italic>) has a protective effect. <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> play a key role in regulating the tumour microenvironment compared with 38 other inflammatory factors that do not show a clear correlation. <italic toggle="yes">IL-1RA</italic> may promote cancer cell proliferation by activating pro-inflammatory signalling pathways, while <italic toggle="yes">B-NGF</italic> may enhance angiogenesis and immune escape, accelerating tumour progression. Conversely, <italic toggle="yes">M-CSF</italic> may reduce thyroid cancer risk by enhancing the anti-tumour immune response. Additionally, single-nucleotide polymorphism survival prognostic analysis showed that specific genetic variants associated with <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> may influence overall survival (OS) and cancer-specific survival (CSS) in patients with thyroid cancer, further supporting their potential value in thyroid cancer management. These findings suggest that <italic toggle="yes">IL-1RA</italic> and <italic toggle="yes">B-NGF</italic> could serve as novel biomarkers for early detection and disease monitoring of thyroid cancer, while <italic toggle="yes">M-CSF</italic> could be a potential therapeutic target, providing theoretical support for personalised intervention strategies. The results provide a new direction for precision medicine research in thyroid cancer.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-025-03533-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Thyroid cancer</kwd><kwd>Mendelian randomisation</kwd><kwd>Inflammatory cytokines</kwd><kwd>Causal relationship</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The incidence of thyroid cancer, a significant global health issue, has been increasing in recent decades [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. Although survival rates are generally high, treatment outcomes vary according to cancer subtype, stage at diagnosis, and patient age [<xref ref-type="bibr" rid="CR4">4</xref>]. Current treatments, including surgery, radioactive iodine therapy, and thyroid hormone therapy, can cause hypothyroidism and lifelong medication dependence [<xref ref-type="bibr" rid="CR5">5</xref>]. This highlights the need for a deeper understanding of the pathogenesis of thyroid cancer, identification of risk factors, and guidance for prevention and control, which are crucial for reducing the incidence and mortality rates of thyroid cancer and improving public health.</p><p id="Par3">The aetiology of thyroid cancer is multifaceted and is believed to be associated with exposure to ionising radiation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], female reproductive factors [<xref ref-type="bibr" rid="CR8">8</xref>], environmental pollution [<xref ref-type="bibr" rid="CR9">9</xref>], dietary patterns [<xref ref-type="bibr" rid="CR10">10</xref>], and lifestyle choices [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, inflammation is increasingly being recognised as a key factor in the development and metastasis of diverse cancers, including thyroid cancer [<xref ref-type="bibr" rid="CR12">12</xref>]. Studies have shown that inflammatory cytokines and chemokines can modulate the tumour microenvironment, affecting tumour growth, angiogenesis, and immune evasion [<xref ref-type="bibr" rid="CR13">13</xref>]. The overactivation of inflammatory markers, such as interleukins (IL), can contribute to the onset of thyroid cancer through systemic inflammation [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. Previous clinical studies have suggested that IL-1&#946;, IL-2, IL-27, and tumour necrosis factor (TNF)-&#945; could serve as biomarkers for the diagnosis and monitoring of thyroid cancer progression [<xref ref-type="bibr" rid="CR17">17</xref>]. Additionally, results from the European Prospective Investigation into Cancer and Nutrition (EPIC) indicate that IL-10, IL-12A, and IL-4I1 may serve as potential indicators for the onset of thyroid cancer [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. IL-17 and TNF-&#945; are potential prognostic markers for patients with Hashimoto's disease complicated by thyroid cancer [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, vascular endothelial growth factor (VEGF) stimulates angiogenesis and increases vascular permeability, which is generally considered a marker of tumour invasiveness. Moreover, studies have found that increased <italic toggle="yes">VEGF</italic> expression in papillary thyroid carcinoma is positively correlated with serum levels of thyroid-stimulating hormone [<xref ref-type="bibr" rid="CR22">22</xref>], and its genotype may play a protective role in the development of differentiated thyroid cancer [<xref ref-type="bibr" rid="CR23">23</xref>]. In particular, VEGF-C and its receptor VEGFR-3 have been demonstrated to play a role in promoting lymphangiogenesis and angiogenesis, which are crucial for thyroid cancer progression and metastasis [<xref ref-type="bibr" rid="CR24">24</xref>]. However, bidirectional Mendelian randomisation (MR) studies have not found a causal relationship between <italic toggle="yes">VEGF</italic> and thyroid cancer [<xref ref-type="bibr" rid="CR25">25</xref>]. Although the role of VEGF in angiogenesis is well established, the lack of MR causality may reflect genetic heterogeneity in thyroid cancer subtypes or compensatory pathways in the tumour microenvironment. This may be limited by insufficient GWAS sample size, making the effect of VEGF-associated genetic variants on thyroid cancer risk difficult to detect. In addition, VEGF mainly affects the stage of tumour progression, while MR studies mainly explore long-term genetic effects, and it is difficult to capture its short-term dynamic effects. Based on the above, existing evidence on the relationship between inflammatory markers and thyroid cancer is inconsistent, primarily observational, and susceptible to confounding and reverse causality, which may hinder accurate causal inference. Thus, further research is required to clarify these connections.</p><p id="Par4">MR uses genetic variants as instrumental variables (IVs) to deduce causal effects and minimise reverse causality [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. With advancements in genome-wide association studies (GWAS) and molecular mechanisms, MR has been used extensively to explore disease risk factors [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Currently, only one MR study has examined the link between inflammatory cytokines and autoimmune thyroid diseases, revealing that specific cytokine levels are linked to the risk of developing Graves&#8217; disease and Hashimoto's thyroiditis [<xref ref-type="bibr" rid="CR30">30</xref>]. However, the association between multiple inflammatory markers and thyroid cancer has not yet been explored. Therefore, this study aimed to investigate the causal relationship between 41 inflammatory factors and the risk of thyroid cancer using MR analysis, to identify potential key inflammatory factors and clarify their mechanisms in tumourigenesis. The study also aimed to provide new insights for the development of biomarkers and personalised treatment strategies. First, IL-1RA and B-NGF, as potential pathogenic factors for thyroid cancer, could be used for early risk prediction and as serum biomarkers for disease monitoring. Furthermore, the single-nucleotide polymorphisms (SNPs) associated with these inflammatory factors could be used to construct polygenic risk scores, thereby improving the early identification rate of high-risk populations. Second, macrophage colony-stimulating factor (M-CSF) may exert protective effects by regulating tumour-associated macrophages, suggesting its potential application in immunomodulatory therapy. Therefore, the study's findings could provide potential biomarkers for the early diagnosis of thyroid cancer and new therapeutic targets for precision treatment strategies, thereby enhancing the clinical value of personalised interventions. The study flow chart is shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>MR schematic illustrating the association between inflammatory factors and thyroid cancer. <bold>a</bold> The MR design is based on three key assumptions. <bold>b</bold> An overview of the analytical approach. MR, Mendelian randomisation</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12672_2025_3533_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>MR study design</title><p id="Par5">The study used MR analysis based on three basic assumptions: (1) Correlation: The selected genetic tool must have a significant and robust correlation with the exposure variable (inflammatory factor) to ensure that the instrumental variable can effectively predict exposure levels; (2) Independence: Genetic variation should be independent of any potential confounding factors, meaning that the association between instrumental variables and study results is established only by exposure variables and is not influenced by environmental factors or other genetic factors; (3) Exclusion restriction: Genetic variation should affect the outcome variable (thyroid cancer) only through exposure variables (inflammatory factors), and should not have indirect effects through other biological pathways, which may lead to horizontal pleiotropy and thus affect the accuracy of causal inference (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). These assumptions align with the MR principles described by Smith et al [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec4"><title>Data sources</title><p id="Par6">Relevant data were sourced from two publicly published GWAS databases (website accessed on 2023&#8211;11-03). The dataset on inflammatory markers was retrieved from the University of Bristol&#8217;s research data repository (<ext-link ext-link-type="uri" xlink:href="https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x">https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x</ext-link>). This dataset contains a meta-analysis of summary statistics for the inflammatory cytokine GWAS performed in 8,293 participants from three Finnish cohorts (YFS: n&#8201;=&#8201;2,136; FINRISK 1997: n&#8201;=&#8201;3,021; FINRISK 2002: n&#8201;=&#8201;3,136). Since the GWAS in ebi-a-GCST90018929 and the data.bris Research Data Repository are published studies, ethical committee approval and informed consent were not required for this study. All procedures were conducted in accordance with local ethical guidelines and regulations. In addition, the GWAS dataset is primarily based on thyroid cancer in European patients, the vast majority of whom have differentiated thyroid cancer, including papillary and follicular subtypes. Due to the small sample sizes of undifferentiated and medullary thyroid cancers in the GWAS data, the hypotheses and conclusions of this study mainly apply to differentiated thyroid cancer.</p></sec><sec id="Sec5"><title>Selection of IVs</title><p id="Par7">Based on the three core assumptions, the selection of IVs was conducted as follows: meaningful SNPs were selected from the GWAS summary data of inflammatory factors, using P&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>&#8211;8</sup> as the criterion for strong correlation; the linkage disequilibrium coefficient r<sup>2</sup> was set at 0.001, and the linkage disequilibrium region width was defined as 10,000&#160;kb to ensure the independence of SNPs and the pleiotropic effect on the results. SNPs associated with confounding factors and outcomes were excluded using Pheno Scanner; a threshold F-statistic value&#8201;&gt;&#8201;10 was used as the criterion to assess weak IVs. Relevant SNPs from the GWAS summary data on thyroid cancer were selected with a minimum r<sup>2</sup>&#8201;&gt;&#8201;0.8. Information from these datasets was consolidated, excluding SNPs directly associated with thyroid cancer (P&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>&#8211;8</sup>). By following these IV selection criteria, the validity and reliability of the causal inference analysis were ensured (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b).</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par8">Statistical analysis was divided into three parts: Causal analysis, sensitivity analysis, and SNP prognostic evaluation. The primary analysis utilised five regression models: the random-effects IVW method, MR-Egger regression, WME, weighted model, and simple model, with SNPs as IVs, to verify the causal relationship between exposure (41 inflammatory markers) and outcome (thyroid cancer). The random-effects IVW method was primarily employed to analyse these causal relationships, with MR-Egger regression and the other three methods serving as supplementary analytical techniques. These methods were implemented using the TwoSampleMR 0.5.7 package in R software version 4.2.2, with a significance level of &#945;&#8201;=&#8201;0.05. The MR analysis code employed in this study is available at <ext-link ext-link-type="uri" xlink:href="https://mrcieu.github.io/TwoSampleMR/articles/index.html">https://mrcieu.github.io/TwoSampleMR/articles/index.html</ext-link>.</p><p id="Par9">Sensitivity analysis included heterogeneity and pleiotropy analyses. Cochran&#8217;s Q test was used to determine SNP heterogeneity; if P&#8201;&lt;&#8201;0.05, the results were considered heterogeneous. I<sup>2</sup> (I-squared) is a statistic applied to measure heterogeneity, indicating the proportion of total variation attributed to heterogeneity. The I<sup>2</sup> values ranged from 0 to 100%, with higher values reflecting greater heterogeneity. The formula for calculating I<sup>2</sup> is I<sup>2</sup>&#8201;=&#8201;(Q&#8212;Q_df)/Q. Pleiotropy analysis was assessed using the intercept from the MR-Egger method, where a non-zero intercept in the MR-Egger regression model (P&#8201;&gt;&#8201;0.05) indicated no evidence of pleiotropy. A leave-one-out analysis was performed by removing each SNP sequentially and reanalysing the remaining SNPs to assess the influence of each SNP on the results.</p><p id="Par10">SNP prognosis survival analysis was conducted using the SUMMER online platform (<ext-link ext-link-type="uri" xlink:href="http://njmu-edu.cn:3838/SUMMER/">http://njmu-edu.cn:3838/SUMMER/</ext-link>, Survival related cancer Multi-omics database via MEndelian Randomisation). The SUMMER system systematically evaluates the causal effects of risk factors and biomarkers on cancer survival, helping to elucidate the genetic mechanisms influencing cancer survival.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Selection of SNPs as IVs</title><p id="Par11">After a rigorous selection process, 836 SNPs were included in the thyroid cancer dataset. The F-statistics for individual SNPs ranged from 19.450 to 782.452 (mean: 32.364), suggesting a low likelihood that the causal association will be influenced by weak IVs.</p></sec><sec id="Sec9"><title>Causal relationship between 41 circulating inflammatory cytokines and thyroid cancer</title><p id="Par12">Using the ebi-a-GCST90018929 dataset for MR analysis, the inverse variance weighted (IVW) analysis results indicated that IL-1 receptor antagonist (<italic toggle="yes">IL-1RA</italic>) and beta-nerve growth factor (<italic toggle="yes">B-NGF</italic>) were risk factors for thyroid cancer, whereas <italic toggle="yes">M-CSF</italic> acted as a protective factor. The remaining 38 inflammatory cytokines were not associated with the risk of thyroid cancer. Regarding the causal relationship between <italic toggle="yes">IL-1RA</italic> and thyroid cancer, the IVW model showed that for each unit increase in <italic toggle="yes">IL-1RA</italic>, the risk of developing thyroid cancer increased by 1.2164 times, with statistical significance (odds ratio [OR]&#8201;=&#8201;1.2164, 95% confidence interval [CI]: 1.0020&#8211;1.4767, P&#8201;=&#8201;0.0477). However, the MR-Egger regression, weighted median estimator (WME) analysis, weighted model, and simple model did not demonstrate any statistically significant results. Thus, based on the IVW results, <italic toggle="yes">IL-1RA</italic> was identified as a risk factor for thyroid carcinoma. For <italic toggle="yes">B-NGF</italic>, the IVW model indicated that each unit increase in <italic toggle="yes">B-NGF</italic> significantly raised the risk of thyroid cancer by 1.2436 times (OR&#8201;=&#8201;1.2436, 95% CI: 1.0193&#8211;1.5173, P&#8201;=&#8201;0.0317). Although the MR-Egger regression, WME analysis, weighted model, and simple model did not yield statistically significant differences, the IVW results consistently indicated that <italic toggle="yes">B-NGF</italic> was linked to an elevated risk of thyroid cancer.</p><p id="Par13">During the causal analysis of <italic toggle="yes">M-CSF</italic> and thyroid cancer, the IVW model demonstrated that each unit increase in <italic toggle="yes">M-CSF</italic> significantly reduced the risk of developing thyroid cancer by 0.8577 times (OR&#8201;=&#8201;0.8577, 95% CI 0.7531&#8211;0.9768, P&#8201;=&#8201;0.0207). Notably, although the MR-Egger regression suggested a reduction in risk by 0.8053 times with each unit increase in <italic toggle="yes">M-CSF</italic>, this was not statistically significant (OR&#8201;=&#8201;0.8053, 95% CI 0.5958&#8211;1.0885, P&#8201;=&#8201;0.1809). Moreover, the WME analysis, weighted model, and simple model showed no statistically significant differences. Based on the IVW results, <italic toggle="yes">M-CSF</italic> was considered a protective factor against thyroid cancer. The remaining 38 inflammatory cytokines, including <italic toggle="yes">IL-18</italic>, did not correlate with the risk of thyroid cancer (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). These results revealed an overall trend in the association between SNPs and thyroid carcinoma risk. To study the functional characteristics and biological correlations of the identified genes (<italic toggle="yes">IL1RN</italic>, <italic toggle="yes">NGF</italic>, and <italic toggle="yes">CSF1</italic>), we performed functional enrichment analysis, and the results are shown in Supplementary Figs.&#160;1 and 2.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Forest plot of results from the MR regression analysis of causal associations. <italic toggle="yes">B-NGF</italic> beta nerve growth factor, <italic toggle="yes">CTACK</italic> cutaneous T cell-attracting chemokine, <italic toggle="yes">FGFBasic</italic> basic fibroblast growth factor, <italic toggle="yes">GCSF</italic> granulocyte colony-stimulating factor, <italic toggle="yes">GROa</italic> growth-regulated oncogene-a, <italic toggle="yes">HGF</italic> hepatocyte growth factor, <italic toggle="yes">IFNg</italic>, interferon-gamma, <italic toggle="yes">IL</italic> interleukin, <italic toggle="yes">IF-10</italic> interferon gamma-induced protein 10, <italic toggle="yes">MCP1</italic> monocyte chemotactic protein 1, <italic toggle="yes">MCP3</italic> monocyte-specific chemokine 3, <italic toggle="yes">MCSF</italic> macrophage colony-stimulating factor, <italic toggle="yes">MIF</italic> macrophage migration inhibitory factor, <italic toggle="yes">MIG</italic> monokine induced by interferon-gamma, <italic toggle="yes">MIP1a</italic> macrophage inflammatory protein-1a, <italic toggle="yes">MIP1b</italic> macrophage inflammatory protein-1b, <italic toggle="yes">MR</italic> Mendelian randomisation, <italic toggle="yes">PDGFbb</italic> platelet-derived growth factor-BB, <italic toggle="yes">RANTES</italic> regulated upon activation normal T cell expressed and secreted factor, <italic toggle="yes">SCF</italic> stem cell factor, <italic toggle="yes">SCGFb</italic> stem cell growth factor beta, <italic toggle="yes">SDF1a</italic> stromal cell-derived factor-1 alpha, <italic toggle="yes">TNFa</italic> tumour necrosis factor alpha, <italic toggle="yes">TNFb</italic> tumour necrosis factor beta, <italic toggle="yes">TRAIL</italic> TNF-related apoptosis-inducing ligand, <italic toggle="yes">VEGF</italic> vascular endothelial growth factor</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12672_2025_3533_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Sensitivity analysis</title><p id="Par14">Heterogeneity was evaluated using Cochran&#8217;s Q test and I<sup>2</sup> statistic, with results indicating no significant heterogeneity in the <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, or <italic toggle="yes">M-CSF</italic> levels. The specific values are listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Pleiotropy was analysed using the intercepts from the MR-Egger regression model. The differences between the MR-Egger intercepts and those of <italic toggle="yes">IL-1RA</italic> and <italic toggle="yes">B-NGF</italic> were not statistically significant (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). For <italic toggle="yes">M-CSF</italic>, the intercept difference from zero was also not statistically significant (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). These results indicate no significant pleiotropy for the analysed factors. Scatter and funnel plots for <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> demonstrated that the SNP distributions were generally symmetrical, suggesting a low likelihood of bias impacting the causal associations (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>MR heterogeneity and horizontal pleiotropy analysis results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Exposure</th><th align="left" colspan="3" rowspan="1">Heterogeneity</th><th align="left" colspan="3" rowspan="1">Horizontal pleiotropy</th></tr><tr><th align="left" colspan="1" rowspan="1">Cochran&#8217;s Q</th><th align="left" colspan="1" rowspan="1">P-value</th><th align="left" colspan="1" rowspan="1">I2</th><th align="left" colspan="1" rowspan="1">Egger intercept</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">IL_ 18</td><td char="." align="char" colspan="1" rowspan="1">25.8824</td><td char="." align="char" colspan="1" rowspan="1">0.3592</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0554</td><td char="." align="char" colspan="1" rowspan="1">0.0229</td><td char="." align="char" colspan="1" rowspan="1">0.0241</td></tr><tr><td align="left" colspan="1" rowspan="1">GROA</td><td char="." align="char" colspan="1" rowspan="1">18.4992</td><td char="." align="char" colspan="1" rowspan="1">0.4233</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.0004</td><td char="." align="char" colspan="1" rowspan="1">0.029</td><td char="." align="char" colspan="1" rowspan="1">0.9899</td></tr><tr><td align="left" colspan="1" rowspan="1">MIP_ 1A</td><td char="." align="char" colspan="1" rowspan="1">14.5594</td><td char="." align="char" colspan="1" rowspan="1">0.4836</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0177</td><td char="." align="char" colspan="1" rowspan="1">0.0397</td><td char="." align="char" colspan="1" rowspan="1">0.6623</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_7</td><td char="." align="char" colspan="1" rowspan="1">8.2023</td><td char="." align="char" colspan="1" rowspan="1">0.9755</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0213</td><td char="." align="char" colspan="1" rowspan="1">0.0303</td><td char="." align="char" colspan="1" rowspan="1">0.4921</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">VEGF</italic></td><td char="." align="char" colspan="1" rowspan="1">42.477</td><td char="." align="char" colspan="1" rowspan="1">0.0508</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.043</td><td char="." align="char" colspan="1" rowspan="1">0.0214</td><td char="." align="char" colspan="1" rowspan="1">0.0541</td></tr><tr><td align="left" colspan="1" rowspan="1">RANTES</td><td char="." align="char" colspan="1" rowspan="1">14.0311</td><td char="." align="char" colspan="1" rowspan="1">0.4474</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0227</td><td char="." align="char" colspan="1" rowspan="1">0.0395</td><td char="." align="char" colspan="1" rowspan="1">0.5752</td></tr><tr><td align="left" colspan="1" rowspan="1">SDF_ 1A</td><td char="." align="char" colspan="1" rowspan="1">16.1905</td><td char="." align="char" colspan="1" rowspan="1">0.6445</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0083</td><td char="." align="char" colspan="1" rowspan="1">0.0205</td><td char="." align="char" colspan="1" rowspan="1">0.692</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_9</td><td char="." align="char" colspan="1" rowspan="1">11.2793</td><td char="." align="char" colspan="1" rowspan="1">0.664</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0376</td><td char="." align="char" colspan="1" rowspan="1">0.05</td><td char="." align="char" colspan="1" rowspan="1">0.4649</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_4</td><td char="." align="char" colspan="1" rowspan="1">16.5025</td><td char="." align="char" colspan="1" rowspan="1">0.7902</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0327</td><td char="." align="char" colspan="1" rowspan="1">0.0232</td><td char="." align="char" colspan="1" rowspan="1">0.1732</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_6</td><td char="." align="char" colspan="1" rowspan="1">8.6216</td><td char="." align="char" colspan="1" rowspan="1">0.9514</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0111</td><td char="." align="char" colspan="1" rowspan="1">0.0276</td><td char="." align="char" colspan="1" rowspan="1">0.6935</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF_BASIC</td><td char="." align="char" colspan="1" rowspan="1">22.5791</td><td char="." align="char" colspan="1" rowspan="1">0.2073</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0161</td><td char="." align="char" colspan="1" rowspan="1">0.0341</td><td char="." align="char" colspan="1" rowspan="1">0.643</td></tr><tr><td align="left" colspan="1" rowspan="1">M_CSF</td><td char="." align="char" colspan="1" rowspan="1">13.9998</td><td char="." align="char" colspan="1" rowspan="1">0.5255</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.022</td><td char="." align="char" colspan="1" rowspan="1">0.0485</td><td char="." align="char" colspan="1" rowspan="1">0.6564</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 12_P70</td><td char="." align="char" colspan="1" rowspan="1">20.9747</td><td char="." align="char" colspan="1" rowspan="1">0.694</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0172</td><td char="." align="char" colspan="1" rowspan="1">0.0177</td><td char="." align="char" colspan="1" rowspan="1">0.3419</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">TNF</italic>_A</td><td char="." align="char" colspan="1" rowspan="1">4.0829</td><td char="." align="char" colspan="1" rowspan="1">0.3949</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0737</td><td char="." align="char" colspan="1" rowspan="1">0.0473</td><td char="." align="char" colspan="1" rowspan="1">0.2169</td></tr><tr><td align="left" colspan="1" rowspan="1">CTACK</td><td char="." align="char" colspan="1" rowspan="1">18.4992</td><td char="." align="char" colspan="1" rowspan="1">0.4233</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.0004</td><td char="." align="char" colspan="1" rowspan="1">0.029</td><td char="." align="char" colspan="1" rowspan="1">0.9899</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 1B</td><td char="." align="char" colspan="1" rowspan="1">11.6061</td><td char="." align="char" colspan="1" rowspan="1">0.2364</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0453</td><td char="." align="char" colspan="1" rowspan="1">0.0381</td><td char="." align="char" colspan="1" rowspan="1">0.268</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_5</td><td char="." align="char" colspan="1" rowspan="1">25.7442</td><td char="." align="char" colspan="1" rowspan="1">0.0792</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">0.0689</td><td char="." align="char" colspan="1" rowspan="1">0.0378</td><td char="." align="char" colspan="1" rowspan="1">0.0874</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 16</td><td char="." align="char" colspan="1" rowspan="1">16.0515</td><td char="." align="char" colspan="1" rowspan="1">0.5202</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0375</td><td char="." align="char" colspan="1" rowspan="1">0.0255</td><td char="." align="char" colspan="1" rowspan="1">0.1609</td></tr><tr><td align="left" colspan="1" rowspan="1">MCP_ 1_MCAF</td><td char="." align="char" colspan="1" rowspan="1">20.4833</td><td char="." align="char" colspan="1" rowspan="1">0.8462</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0105</td><td char="." align="char" colspan="1" rowspan="1">0.0244</td><td char="." align="char" colspan="1" rowspan="1">0.671</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 10</td><td char="." align="char" colspan="1" rowspan="1">24.8774</td><td char="." align="char" colspan="1" rowspan="1">0.2525</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0341</td><td char="." align="char" colspan="1" rowspan="1">0.0239</td><td char="." align="char" colspan="1" rowspan="1">0.1688</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_2</td><td char="." align="char" colspan="1" rowspan="1">16.6731</td><td char="." align="char" colspan="1" rowspan="1">0.612</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0314</td><td char="." align="char" colspan="1" rowspan="1">0.0273</td><td char="." align="char" colspan="1" rowspan="1">0.2657</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 13</td><td char="." align="char" colspan="1" rowspan="1">18.6733</td><td char="." align="char" colspan="1" rowspan="1">0.7692</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0469</td><td char="." align="char" colspan="1" rowspan="1">0.023</td><td char="." align="char" colspan="1" rowspan="1">0.0526</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 17</td><td char="." align="char" colspan="1" rowspan="1">20.1966</td><td char="." align="char" colspan="1" rowspan="1">0.3828</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">0.0349</td><td char="." align="char" colspan="1" rowspan="1">0.0341</td><td char="." align="char" colspan="1" rowspan="1">0.3189</td></tr><tr><td align="left" colspan="1" rowspan="1">MIG</td><td char="." align="char" colspan="1" rowspan="1">21.2618</td><td char="." align="char" colspan="1" rowspan="1">0.2664</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0441</td><td char="." align="char" colspan="1" rowspan="1">0.0365</td><td char="." align="char" colspan="1" rowspan="1">0.2435</td></tr><tr><td align="left" colspan="1" rowspan="1">IFN_G</td><td char="." align="char" colspan="1" rowspan="1">17.9669</td><td char="." align="char" colspan="1" rowspan="1">0.3258</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">0.018</td><td char="." align="char" colspan="1" rowspan="1">0.0317</td><td char="." align="char" colspan="1" rowspan="1">0.5788</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">TNF</italic>_B</td><td char="." align="char" colspan="1" rowspan="1">9.3287</td><td char="." align="char" colspan="1" rowspan="1">0.5012</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0284</td><td char="." align="char" colspan="1" rowspan="1">0.0314</td><td char="." align="char" colspan="1" rowspan="1">0.3896</td></tr><tr><td align="left" colspan="1" rowspan="1">SCF</td><td char="." align="char" colspan="1" rowspan="1">17.0825</td><td char="." align="char" colspan="1" rowspan="1">0.6476</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0091</td><td char="." align="char" colspan="1" rowspan="1">0.021</td><td char="." align="char" colspan="1" rowspan="1">0.6699</td></tr><tr><td align="left" colspan="1" rowspan="1">TRAIL</td><td char="." align="char" colspan="1" rowspan="1">25.4848</td><td char="." align="char" colspan="1" rowspan="1">0.9532</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0013</td><td char="." align="char" colspan="1" rowspan="1">0.0145</td><td char="." align="char" colspan="1" rowspan="1">0.9294</td></tr><tr><td align="left" colspan="1" rowspan="1">SCGF_B</td><td char="." align="char" colspan="1" rowspan="1">23.5322</td><td char="." align="char" colspan="1" rowspan="1">0.6561</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0015</td><td char="." align="char" colspan="1" rowspan="1">0.0234</td><td char="." align="char" colspan="1" rowspan="1">0.9488</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_8</td><td char="." align="char" colspan="1" rowspan="1">7.951</td><td char="." align="char" colspan="1" rowspan="1">0.7177</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0196</td><td char="." align="char" colspan="1" rowspan="1">0.0317</td><td char="." align="char" colspan="1" rowspan="1">0.5504</td></tr><tr><td align="left" colspan="1" rowspan="1">HGF</td><td char="." align="char" colspan="1" rowspan="1">4.0371</td><td char="." align="char" colspan="1" rowspan="1">0.9457</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0004</td><td char="." align="char" colspan="1" rowspan="1">0.0447</td><td char="." align="char" colspan="1" rowspan="1">0.9925</td></tr><tr><td align="left" colspan="1" rowspan="1">PDGF_BB</td><td char="." align="char" colspan="1" rowspan="1">18.0934</td><td char="." align="char" colspan="1" rowspan="1">0.8384</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0192</td><td char="." align="char" colspan="1" rowspan="1">0.0221</td><td char="." align="char" colspan="1" rowspan="1">0.3921</td></tr><tr><td align="left" colspan="1" rowspan="1">MIP_ 1B</td><td char="." align="char" colspan="1" rowspan="1">64.8503</td><td char="." align="char" colspan="1" rowspan="1">0.3776</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0042</td><td char="." align="char" colspan="1" rowspan="1">0.0145</td><td char="." align="char" colspan="1" rowspan="1">0.7725</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_ 1RA</td><td char="." align="char" colspan="1" rowspan="1">16.7561</td><td char="." align="char" colspan="1" rowspan="1">0.3337</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0103</td><td char="." align="char" colspan="1" rowspan="1">0.047</td><td char="." align="char" colspan="1" rowspan="1">0.8293</td></tr><tr><td align="left" colspan="1" rowspan="1">EOTAXIN</td><td char="." align="char" colspan="1" rowspan="1">43.6546</td><td char="." align="char" colspan="1" rowspan="1">0.0396</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0263</td><td char="." align="char" colspan="1" rowspan="1">0.0295</td><td char="." align="char" colspan="1" rowspan="1">0.3802</td></tr><tr><td align="left" colspan="1" rowspan="1">MIF</td><td char="." align="char" colspan="1" rowspan="1">21.1201</td><td char="." align="char" colspan="1" rowspan="1">0.3302</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0142</td><td char="." align="char" colspan="1" rowspan="1">0.0254</td><td char="." align="char" colspan="1" rowspan="1">0.5838</td></tr><tr><td align="left" colspan="1" rowspan="1">IP_ 10</td><td char="." align="char" colspan="1" rowspan="1">17.1842</td><td char="." align="char" colspan="1" rowspan="1">0.2465</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.0479</td><td char="." align="char" colspan="1" rowspan="1">0.0392</td><td char="." align="char" colspan="1" rowspan="1">0.2436</td></tr><tr><td align="left" colspan="1" rowspan="1">G_CSF</td><td char="." align="char" colspan="1" rowspan="1">18.2313</td><td char="." align="char" colspan="1" rowspan="1">0.507</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.0168</td><td char="." align="char" colspan="1" rowspan="1">0.0206</td><td char="." align="char" colspan="1" rowspan="1">0.4235</td></tr><tr><td align="left" colspan="1" rowspan="1">B_NGF</td><td char="." align="char" colspan="1" rowspan="1">9.5794</td><td char="." align="char" colspan="1" rowspan="1">0.5686</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.1052</td><td char="." align="char" colspan="1" rowspan="1">0.0507</td><td char="." align="char" colspan="1" rowspan="1">0.0648</td></tr><tr><td align="left" colspan="1" rowspan="1">IL_2RA</td><td char="." align="char" colspan="1" rowspan="1">25.3342</td><td char="." align="char" colspan="1" rowspan="1">0.1498</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.006</td><td char="." align="char" colspan="1" rowspan="1">0.0288</td><td char="." align="char" colspan="1" rowspan="1">0.8376</td></tr><tr><td align="left" colspan="1" rowspan="1">MCP_3</td><td char="." align="char" colspan="1" rowspan="1">13.7179</td><td char="." align="char" colspan="1" rowspan="1">0.0564</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">0.0163</td><td char="." align="char" colspan="1" rowspan="1">0.0688</td><td char="." align="char" colspan="1" rowspan="1">0.8201</td></tr></tbody></table></table-wrap><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Scatter and funnel plots of MR analyses for <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> in thyroid cancer. <bold>a</bold>, <bold>c</bold>, <bold>e</bold> Scatter plots show individual instrumental variable (IV) associations with cytokine risk (black dots) plotted against their associations with thyroid cancer. The 95% confidence interval of the odds ratio for each IV is indicated by vertical and horizontal lines. The slope of the lines represents the estimated causal effect from the MR methods. <bold>b</bold>, <bold>d</bold>, <bold>f</bold> The funnel plots display the IV-weighted MR estimate of each cytokine single-nucleotide polymorphism with thyroid cancer versus 1/standard error (1/SEIV). MR, Mendelian randomisation; IV, inverse variance</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="12672_2025_3533_Fig3_HTML.jpg"/></fig></p><p id="Par15">Sensitivity was assessed using the leave-one-out method, which involved sequentially excluding SNPs for <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Our analysis results were consistent with those obtained when all SNPs were included, indicating that no single SNP had a meaningful effect on the causal estimates. This confirms the robustness of the MR results. In addition, the analyses of heterogeneity and pleiotropy performed on <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> were not statistically significant, suggesting that the results are reliable. Additionally, a sensitivity analysis further confirmed the stability of the findings.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Results of the &#8220;leave-one-out&#8221; sensitivity analysis. <bold>a</bold> MR leave-one-out sensitivity analysis for <italic toggle="yes">IL-1RA</italic> in thyroid cancer. <bold>b</bold> MR leave-one-out sensitivity analysis for <italic toggle="yes">B-NGF</italic> in thyroid cancer. <bold>c</bold> MR leave-one-out sensitivity analysis for <italic toggle="yes">M-CSF</italic> in thyroid cancer. MR, Mendelian randomisation; <italic toggle="yes">IL-1RA</italic>, interleukin-1 receptor antagonist; <italic toggle="yes">B-NGF</italic>, beta-nerve growth factor; <italic toggle="yes">M-CSF</italic>, macrophage-colony stimulating factor</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="12672_2025_3533_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>SNP prognosis analysis</title><p id="Par16">SNP information was obtained from SNPs that were significantly associated with inflammatory factors related to thyroid cancer. SUMMER results identified rs71641308 as a risk factor for overall survival (OS) in patients with thyroid cancer (HR&#8201;=&#8201;5.2395, P&#8201;&lt;&#8201;0.01); however, the results for cancer-specific survival (CSS) indicated that rs71641308 was not related to thyroid cancer prognosis (HR&#8201;=&#8201;115,973.3083, P&#8201;=&#8201;0.0977). The SNPs rs11869294, rs116274860, and rs62294910 were not associated with OS prognosis in thyroid cancer (HR&#8201;=&#8201;1.8224, 10.1573, and 2.3126, respectively; P&#8201;&gt;&#8201;0.05); however, the CSS results suggested that rs11869294, rs116274860, and rs62294910 were risk factors for thyroid cancer prognosis (HR&#8201;=&#8201;61.4871, 90.4400, and 304.5627, respectively; P&#8201;&lt;&#8201;0.05). In addition, the SNP rs187166731 was identified as a risk factor for OS (HR&#8201;=&#8201;43.1384, P&#8201;&lt;&#8201;0.01) and CSS (HR&#8201;=&#8201;23,470.9553, P&#8201;&lt;&#8201;0.05) in thyroid cancer (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). These results suggest that <italic toggle="yes">IL-1RA</italic>, <italic toggle="yes">B-NGF</italic>, and <italic toggle="yes">M-CSF</italic> are relevant to the prognosis of thyroid cancer.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>SNP prognostic analysis results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">CHR</th><th align="left" colspan="1" rowspan="1">SNP</th><th align="left" colspan="1" rowspan="1">BP hg19</th><th align="left" colspan="1" rowspan="1">A1</th><th align="left" colspan="1" rowspan="1">A2</th><th align="left" colspan="1" rowspan="1">MAF</th><th align="left" colspan="1" rowspan="1">HR OS</th><th align="left" colspan="1" rowspan="1">SE OS</th><th align="left" colspan="1" rowspan="1">P value OS</th><th align="left" colspan="1" rowspan="1">HR CSS</th><th align="left" colspan="1" rowspan="1">SE CSS</th><th align="left" colspan="1" rowspan="1">P value CSS</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">B-NGF</italic></td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">rs71641308</td><td align="left" colspan="1" rowspan="1">78,086,718</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0669</td><td align="left" colspan="1" rowspan="1">5.2395</td><td char="." align="char" colspan="1" rowspan="1">0.516</td><td char="." align="char" colspan="1" rowspan="1">0.0013</td><td align="left" colspan="1" rowspan="1">115,973.3083</td><td char="." align="char" colspan="1" rowspan="1">7.0405</td><td char="." align="char" colspan="1" rowspan="1">0.0977</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">rs10919178</td><td align="left" colspan="1" rowspan="1">169,473,503</td><td align="left" colspan="1" rowspan="1">C</td><td align="left" colspan="1" rowspan="1">T</td><td char="." align="char" colspan="1" rowspan="1">0.2893</td><td align="left" colspan="1" rowspan="1">1.1788</td><td char="." align="char" colspan="1" rowspan="1">0.4152</td><td char="." align="char" colspan="1" rowspan="1">0.692</td><td align="left" colspan="1" rowspan="1">1.499</td><td char="." align="char" colspan="1" rowspan="1">0.8027</td><td char="." align="char" colspan="1" rowspan="1">0.614</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">rs74966328</td><td align="left" colspan="1" rowspan="1">235,707,209</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.0205</td><td align="left" colspan="1" rowspan="1">2.0023</td><td char="." align="char" colspan="1" rowspan="1">1.0004</td><td char="." align="char" colspan="1" rowspan="1">0.4877</td><td align="left" colspan="1" rowspan="1">4.5779</td><td char="." align="char" colspan="1" rowspan="1">1.8037</td><td char="." align="char" colspan="1" rowspan="1">0.399</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">rs55749192</td><td align="left" colspan="1" rowspan="1">106,354,163</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">A</td><td char="." align="char" colspan="1" rowspan="1">0.2283</td><td align="left" colspan="1" rowspan="1">1.2522</td><td char="." align="char" colspan="1" rowspan="1">0.3723</td><td char="." align="char" colspan="1" rowspan="1">0.5458</td><td align="left" colspan="1" rowspan="1">0.2682</td><td char="." align="char" colspan="1" rowspan="1">1.0235</td><td char="." align="char" colspan="1" rowspan="1">0.1984</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">rs66515854</td><td align="left" colspan="1" rowspan="1">3,891,306</td><td align="left" colspan="1" rowspan="1">C</td><td align="left" colspan="1" rowspan="1">T</td><td char="." align="char" colspan="1" rowspan="1">0.1341</td><td align="left" colspan="1" rowspan="1">0.8558</td><td char="." align="char" colspan="1" rowspan="1">0.6158</td><td char="." align="char" colspan="1" rowspan="1">0.8003</td><td align="left" colspan="1" rowspan="1">1.542</td><td char="." align="char" colspan="1" rowspan="1">1.3104</td><td char="." align="char" colspan="1" rowspan="1">0.741</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">rs1334726</td><td align="left" colspan="1" rowspan="1">63,193,678</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.4045</td><td align="left" colspan="1" rowspan="1">1.2271</td><td char="." align="char" colspan="1" rowspan="1">0.3952</td><td char="." align="char" colspan="1" rowspan="1">0.6045</td><td align="left" colspan="1" rowspan="1">1.3071</td><td char="." align="char" colspan="1" rowspan="1">0.8312</td><td char="." align="char" colspan="1" rowspan="1">0.7473</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">rs75629970</td><td align="left" colspan="1" rowspan="1">17,595,441</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.0335</td><td align="left" colspan="1" rowspan="1">2.1502</td><td char="." align="char" colspan="1" rowspan="1">0.855</td><td char="." align="char" colspan="1" rowspan="1">0.3706</td><td align="left" colspan="1" rowspan="1">3.9101</td><td char="." align="char" colspan="1" rowspan="1">1.3621</td><td char="." align="char" colspan="1" rowspan="1">0.3168</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">rs67476890</td><td align="left" colspan="1" rowspan="1">62,791,494</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0922</td><td align="left" colspan="1" rowspan="1">1.6044</td><td char="." align="char" colspan="1" rowspan="1">0.6542</td><td char="." align="char" colspan="1" rowspan="1">0.4699</td><td align="left" colspan="1" rowspan="1">0.4416</td><td char="." align="char" colspan="1" rowspan="1">1.3291</td><td char="." align="char" colspan="1" rowspan="1">0.5386</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">rs28637706</td><td align="left" colspan="1" rowspan="1">34,285,368</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.3722</td><td align="left" colspan="1" rowspan="1">0.5674</td><td char="." align="char" colspan="1" rowspan="1">0.4499</td><td char="." align="char" colspan="1" rowspan="1">0.2077</td><td align="left" colspan="1" rowspan="1">1.2365</td><td char="." align="char" colspan="1" rowspan="1">0.8405</td><td char="." align="char" colspan="1" rowspan="1">0.8006</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">IL-1RA</italic></td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">rs6699436</td><td align="left" colspan="1" rowspan="1">62,803,032</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.1264</td><td align="left" colspan="1" rowspan="1">1.0279</td><td char="." align="char" colspan="1" rowspan="1">0.6185</td><td char="." align="char" colspan="1" rowspan="1">0.9645</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">10,210.7594</td><td char="." align="char" colspan="1" rowspan="1">0.9983</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">rs12121840</td><td align="left" colspan="1" rowspan="1">165,541,642</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0523</td><td align="left" colspan="1" rowspan="1">1.8392</td><td char="." align="char" colspan="1" rowspan="1">1.0578</td><td char="." align="char" colspan="1" rowspan="1">0.5646</td><td align="left" colspan="1" rowspan="1">32.7178</td><td char="." align="char" colspan="1" rowspan="1">2.5972</td><td char="." align="char" colspan="1" rowspan="1">0.1793</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">rs4441609</td><td align="left" colspan="1" rowspan="1">36,892,717</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.3911</td><td align="left" colspan="1" rowspan="1">0.452</td><td char="." align="char" colspan="1" rowspan="1">0.4632</td><td char="." align="char" colspan="1" rowspan="1">0.0865</td><td align="left" colspan="1" rowspan="1">0.5564</td><td char="." align="char" colspan="1" rowspan="1">0.7554</td><td char="." align="char" colspan="1" rowspan="1">0.4377</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">rs1522921</td><td align="left" colspan="1" rowspan="1">29,149,995</td><td align="left" colspan="1" rowspan="1">C</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.4826</td><td align="left" colspan="1" rowspan="1">0.631</td><td char="." align="char" colspan="1" rowspan="1">0.3924</td><td char="." align="char" colspan="1" rowspan="1">0.2406</td><td align="left" colspan="1" rowspan="1">1.2754</td><td char="." align="char" colspan="1" rowspan="1">0.6926</td><td char="." align="char" colspan="1" rowspan="1">0.7254</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">rs1054402</td><td align="left" colspan="1" rowspan="1">119,163,509</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">0.7587</td><td char="." align="char" colspan="1" rowspan="1">0.5035</td><td char="." align="char" colspan="1" rowspan="1">0.5834</td><td align="left" colspan="1" rowspan="1">0.0286</td><td char="." align="char" colspan="1" rowspan="1">2.0492</td><td char="." align="char" colspan="1" rowspan="1">0.0829</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">rs74435620</td><td align="left" colspan="1" rowspan="1">108,436,318</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">A</td><td char="." align="char" colspan="1" rowspan="1">0.1152</td><td align="left" colspan="1" rowspan="1">0.7881</td><td char="." align="char" colspan="1" rowspan="1">0.6295</td><td char="." align="char" colspan="1" rowspan="1">0.7052</td><td align="left" colspan="1" rowspan="1">0.4818</td><td char="." align="char" colspan="1" rowspan="1">1.4691</td><td char="." align="char" colspan="1" rowspan="1">0.6192</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">rs2809154</td><td align="left" colspan="1" rowspan="1">84,727,524</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.1788</td><td align="left" colspan="1" rowspan="1">1.0951</td><td char="." align="char" colspan="1" rowspan="1">0.5689</td><td char="." align="char" colspan="1" rowspan="1">0.8731</td><td align="left" colspan="1" rowspan="1">1.9649</td><td char="." align="char" colspan="1" rowspan="1">0.9622</td><td char="." align="char" colspan="1" rowspan="1">0.4827</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">rs4566030</td><td align="left" colspan="1" rowspan="1">114,907,255</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">A</td><td char="." align="char" colspan="1" rowspan="1">0.1508</td><td align="left" colspan="1" rowspan="1">2.1585</td><td char="." align="char" colspan="1" rowspan="1">0.5861</td><td char="." align="char" colspan="1" rowspan="1">0.1893</td><td align="left" colspan="1" rowspan="1">2.0024</td><td char="." align="char" colspan="1" rowspan="1">1.0193</td><td char="." align="char" colspan="1" rowspan="1">0.4958</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">rs11627423</td><td align="left" colspan="1" rowspan="1">33,200,623</td><td align="left" colspan="1" rowspan="1">C</td><td align="left" colspan="1" rowspan="1">A</td><td char="." align="char" colspan="1" rowspan="1">0.3616</td><td align="left" colspan="1" rowspan="1">0.6572</td><td char="." align="char" colspan="1" rowspan="1">0.4531</td><td char="." align="char" colspan="1" rowspan="1">0.3541</td><td align="left" colspan="1" rowspan="1">0.0373</td><td char="." align="char" colspan="1" rowspan="1">1.6946</td><td char="." align="char" colspan="1" rowspan="1">0.0524</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">rs61335305</td><td align="left" colspan="1" rowspan="1">66,453,074</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0196</td><td align="left" colspan="1" rowspan="1">2.1545</td><td char="." align="char" colspan="1" rowspan="1">1.1614</td><td char="." align="char" colspan="1" rowspan="1">0.5087</td><td align="left" colspan="1" rowspan="1">9.1856</td><td char="." align="char" colspan="1" rowspan="1">1.4149</td><td char="." align="char" colspan="1" rowspan="1">0.117</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">rs4783191</td><td align="left" colspan="1" rowspan="1">85,419,810</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.2151</td><td align="left" colspan="1" rowspan="1">0.7346</td><td char="." align="char" colspan="1" rowspan="1">0.5255</td><td char="." align="char" colspan="1" rowspan="1">0.5573</td><td align="left" colspan="1" rowspan="1">0.2421</td><td char="." align="char" colspan="1" rowspan="1">1.2246</td><td char="." align="char" colspan="1" rowspan="1">0.2468</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">rs11869294</td><td align="left" colspan="1" rowspan="1">43,857,223</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0698</td><td align="left" colspan="1" rowspan="1">1.8224</td><td char="." align="char" colspan="1" rowspan="1">0.5479</td><td char="." align="char" colspan="1" rowspan="1">0.2733</td><td align="left" colspan="1" rowspan="1">61.4871</td><td char="." align="char" colspan="1" rowspan="1">1.7228</td><td char="." align="char" colspan="1" rowspan="1">0.0168</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">rs187166731</td><td align="left" colspan="1" rowspan="1">42,666,026</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0115</td><td align="left" colspan="1" rowspan="1">43.1384</td><td char="." align="char" colspan="1" rowspan="1">1.4554</td><td char="." align="char" colspan="1" rowspan="1">0.0097</td><td align="left" colspan="1" rowspan="1">23,470.9</td><td char="." align="char" colspan="1" rowspan="1">5.0814</td><td char="." align="char" colspan="1" rowspan="1">0.0477</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">M-CSF</italic></td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">rs78296352</td><td align="left" colspan="1" rowspan="1">22,821,844</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.0391</td><td align="left" colspan="1" rowspan="1">2.6414</td><td char="." align="char" colspan="1" rowspan="1">0.79</td><td char="." align="char" colspan="1" rowspan="1">0.2189</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">10,849.1559</td><td char="." align="char" colspan="1" rowspan="1">0.9986</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">rs34089869</td><td align="left" colspan="1" rowspan="1">67,923,478</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.1006</td><td align="left" colspan="1" rowspan="1">0.5035</td><td char="." align="char" colspan="1" rowspan="1">0.8578</td><td char="." align="char" colspan="1" rowspan="1">0.4237</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">11,676.4 031</td><td char="." align="char" colspan="1" rowspan="1">0.9987</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">rs72818729</td><td align="left" colspan="1" rowspan="1">75,870,247</td><td align="left" colspan="1" rowspan="1">C</td><td align="left" colspan="1" rowspan="1">T</td><td char="." align="char" colspan="1" rowspan="1">0.0961</td><td align="left" colspan="1" rowspan="1">0.4481</td><td char="." align="char" colspan="1" rowspan="1">0.7913</td><td char="." align="char" colspan="1" rowspan="1">0.3103</td><td align="left" colspan="1" rowspan="1">1.4011</td><td char="." align="char" colspan="1" rowspan="1">1.355</td><td char="." align="char" colspan="1" rowspan="1">0.8034</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">rs77137364</td><td align="left" colspan="1" rowspan="1">74,989,832</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0419</td><td align="left" colspan="1" rowspan="1">3.0283</td><td char="." align="char" colspan="1" rowspan="1">0.9021</td><td char="." align="char" colspan="1" rowspan="1">0.2194</td><td align="left" colspan="1" rowspan="1">5.4908</td><td char="." align="char" colspan="1" rowspan="1">1.4377</td><td char="." align="char" colspan="1" rowspan="1">0.2362</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">rs116274860</td><td align="left" colspan="1" rowspan="1">148,392,817</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">T</td><td char="." align="char" colspan="1" rowspan="1">0.0197</td><td align="left" colspan="1" rowspan="1">10.1573</td><td char="." align="char" colspan="1" rowspan="1">1.275</td><td char="." align="char" colspan="1" rowspan="1">0.069</td><td align="left" colspan="1" rowspan="1">90.44</td><td char="." align="char" colspan="1" rowspan="1">2.1018</td><td char="." align="char" colspan="1" rowspan="1">0.0321</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">rs62294910</td><td align="left" colspan="1" rowspan="1">182,198,339</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.0531</td><td align="left" colspan="1" rowspan="1">2.3126</td><td char="." align="char" colspan="1" rowspan="1">0.9238</td><td char="." align="char" colspan="1" rowspan="1">0.3641</td><td align="left" colspan="1" rowspan="1">304.5627</td><td char="." align="char" colspan="1" rowspan="1">2.4825</td><td char="." align="char" colspan="1" rowspan="1">0.0212</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">rs72723242</td><td align="left" colspan="1" rowspan="1">7,262,954</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">G</td><td char="." align="char" colspan="1" rowspan="1">0.0307</td><td align="left" colspan="1" rowspan="1">1.1369</td><td char="." align="char" colspan="1" rowspan="1">1.1388</td><td char="." align="char" colspan="1" rowspan="1">0.9103</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">13,290.0 502</td><td char="." align="char" colspan="1" rowspan="1">0.9988</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">rs11963606</td><td align="left" colspan="1" rowspan="1">4,592,689</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0141</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">8163.3 586</td><td char="." align="char" colspan="1" rowspan="1">0.9983</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">12,773.5 364</td><td char="." align="char" colspan="1" rowspan="1">0.9989</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">rs9387100</td><td align="left" colspan="1" rowspan="1">113,102,954</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.3408</td><td align="left" colspan="1" rowspan="1">0.3584</td><td char="." align="char" colspan="1" rowspan="1">0.5599</td><td char="." align="char" colspan="1" rowspan="1">0.0668</td><td align="left" colspan="1" rowspan="1">0.2234</td><td char="." align="char" colspan="1" rowspan="1">1.0059</td><td char="." align="char" colspan="1" rowspan="1">0.1362</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">rs56367447</td><td align="left" colspan="1" rowspan="1">3,871,527</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0426</td><td align="left" colspan="1" rowspan="1">1.672</td><td char="." align="char" colspan="1" rowspan="1">0.7852</td><td char="." align="char" colspan="1" rowspan="1">0.5127</td><td align="left" colspan="1" rowspan="1">1.2679</td><td char="." align="char" colspan="1" rowspan="1">1.4293</td><td char="." align="char" colspan="1" rowspan="1">0.8681</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">rs117283853</td><td align="left" colspan="1" rowspan="1">30,965,225</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">A</td><td char="." align="char" colspan="1" rowspan="1">0.0343</td><td align="left" colspan="1" rowspan="1">1.29</td><td char="." align="char" colspan="1" rowspan="1">0.896</td><td char="." align="char" colspan="1" rowspan="1">0.7762</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">15,968.7 705</td><td char="." align="char" colspan="1" rowspan="1">0.9991</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">rs12962919</td><td align="left" colspan="1" rowspan="1">75,778,756</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.0971</td><td align="left" colspan="1" rowspan="1">1.6449</td><td char="." align="char" colspan="1" rowspan="1">0.6955</td><td char="." align="char" colspan="1" rowspan="1">0.4743</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">14,037.2 837</td><td char="." align="char" colspan="1" rowspan="1">0.9989</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">rs4269021</td><td align="left" colspan="1" rowspan="1">47,673,948</td><td align="left" colspan="1" rowspan="1">G</td><td align="left" colspan="1" rowspan="1">C</td><td char="." align="char" colspan="1" rowspan="1">0.1376</td><td align="left" colspan="1" rowspan="1">0.1557</td><td char="." align="char" colspan="1" rowspan="1">1.1495</td><td char="." align="char" colspan="1" rowspan="1">0.1057</td><td align="left" colspan="1" rowspan="1">0.5525</td><td char="." align="char" colspan="1" rowspan="1">1.4633</td><td char="." align="char" colspan="1" rowspan="1">0.6851</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CHR</italic> chromosome, <italic toggle="yes">SNP</italic> single nucleotide polymorphism, <italic toggle="yes">BP_hg19</italic> position of the SNP on the hg19 reference genome, <italic toggle="yes">A1</italic> effect allele, <italic toggle="yes">A2</italic> other allele, <italic toggle="yes">MAF</italic> minor allele frequency, <italic toggle="yes">HR_OS</italic> hazard ratio for overall survival, <italic toggle="yes">SE_OS</italic> standard error for overall survival analysis, <italic toggle="yes">P_value_OS</italic> p-value for overall survival analysis, <italic toggle="yes">HR_CSS</italic> hazard ratio for cancer-specific survival, <italic toggle="yes">SE_CSS</italic> standard error for cancer-specific survival analysis, <italic toggle="yes">P-value_CSS</italic> p-value for cancer-specific survival analysis</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par17">As a disease affecting the endocrine system, thyroid cancer can lead to various health complications, including hormonal imbalances. If left untreated, it may metastasise to other parts of the body, causing further damage [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, inflammation is a key process in the pathogenesis of various cancers, including thyroid cancer [<xref ref-type="bibr" rid="CR33">33</xref>]. Therefore, exploring the causal relationship between inflammatory factors and thyroid cancer may provide new directions for developing novel diagnostic and therapeutic strategies. In this study, we identified 836 SNPs as IVs using MR to explore the causal relationship between 41 circulating inflammatory factors and thyroid cancer risk. These results indicated that <italic toggle="yes">IL-1RA</italic> and <italic toggle="yes">B-NGF</italic> are risk factors for the onset of thyroid cancer, whereas <italic toggle="yes">M-CSF</italic> serves as a protective factor. To date, our research is the first to identify and establish a causal relationship between circulating inflammatory factors and thyroid cancer.</p><p id="Par18">IL-1RA regulates the inflammatory response mainly by competitively inhibiting the receptor binding of IL-1&#945; and IL-1&#946; and affecting signalling pathways such as NF-&#954;B [<xref ref-type="bibr" rid="CR34">34</xref>]. IL-1RA plays different roles in various types of cancer [<xref ref-type="bibr" rid="CR35">35</xref>]. For example, in oral squamous cell carcinoma, it promotes tumour progression by affecting mitochondrial metabolism and is associated with a poor prognosis, potentially influencing cancer cell energy supply and proliferation [<xref ref-type="bibr" rid="CR36">36</xref>]. In colorectal cancer, IL-1RA reduces cancer cell metastatic potential by inhibiting the CXCL12/CXCR4 signalling axis, suggesting that it may have anti-metastatic effects in certain cancers [<xref ref-type="bibr" rid="CR37">37</xref>]. In thyroid cancer, particularly in anaplastic thyroid carcinoma and follicular thyroid carcinoma, elevated IL-1RA may influence the tumour microenvironment through the IL-1&#946; signalling pathway, altering inflammatory responses and immune cell infiltration, thereby regulating tumour cell growth and differentiation [<xref ref-type="bibr" rid="CR38">38</xref>]. This indicates that the role of IL-1RA in thyroid cancer may be more complex, with different inflammatory states and immune regulation determining its specific effects [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. The duality of IL-1RA in tumour biology suggests that although IL-1RA can prevent tumour progression by inhibiting the inflammatory response in some cases, in others, it instead promotes tumour growth and metastasis by suppressing the anti-tumour response of the immune system. The specific manifestations of this duality in thyroid cancer have not been fully elucidated; however, IL-1RA has been proposed to influence cancer progression through a complex cytokine network and immune escape mechanisms [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par19">In summary, the role of IL-1RA in thyroid cancer is similar to that of other cancers, although it also has its own unique pathway and mechanism, which provides a theoretical basis for its use as a potential therapeutic target. Future studies could further explore the specific molecular mechanisms of IL-1RA in thyroid cancer to help better understand its role in cancer progression and develop new therapeutic strategies.</p><p id="Par20"><italic toggle="yes">B-NGF</italic> primarily promotes the growth, differentiation, and maturation of central and peripheral neurons, all while maintaining the physiological functions of the nervous system [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Moreover, recent studies have shown that it also plays an important role in various non-neurological physiological and pathological processes, including tumourigenesis. B-NGF promotes tumour progression by enhancing angiogenesis and cell survival [<xref ref-type="bibr" rid="CR44">44</xref>]. Additionally, B-NGF is involved in immunomodulation, directly affecting innate and adaptive immune responses in B and T cells, as well as regulating immune system activation in tissues [<xref ref-type="bibr" rid="CR45">45</xref>]. These findings suggest that B-NGF likely plays a role in the pathogenesis of thyroid cancer by promoting the proliferation and differentiation of tumour cells, as well as regulating immune responses. This is consistent with our finding that <italic toggle="yes">B-NGF</italic> was associated with an increased risk of thyroid cancer. Thus, we highlight the importance of <italic toggle="yes">B-NGF</italic> as a risk factor for thyroid cancer and suggest that it may serve as a novel target for cancer therapy.</p><p id="Par21">In contrast, in our study, a reduced risk of thyroid cancer was associated with <italic toggle="yes">M-CSF</italic>, which influences macrophage differentiation and survival. Typically, <italic toggle="yes">M-CSF</italic> is commonly overexpressed in tumours and is thought to enhance tumour growth and invasiveness by stimulating the growth and differentiation of tumour-associated macrophages [<xref ref-type="bibr" rid="CR46">46</xref>]. Interestingly, our findings identifying <italic toggle="yes">M-CSF</italic> as a protective factor against thyroid cancer are consistent with previous studies on the complex role of <italic toggle="yes">M-CSF</italic> in carcinogenesis. M-CSF&#8217;s protective effect might arise from its ability to polarise tumour-associated macrophages (TAMs) toward an anti-tumour M1 phenotype in thyroid microenvironments, as shown in colorectal cancer models [<xref ref-type="bibr" rid="CR47">47</xref>]. IL-12 secreted during polarisation stimulates cytotoxic T cells and counteracts IL-1RA-mediated immunosuppression, suggesting a therapeutic synergy between M-CSF agonists and IL-1RA inhibitors [<xref ref-type="bibr" rid="CR48">48</xref>]. Under certain conditions, M-CSF may inhibit tumour growth and metastasis, possibly by modulating inflammatory responses and promoting immune surveillance to reduce the risk of thyroid cancer [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Thus, the observed protective effects of <italic toggle="yes">M-CSF</italic> may facilitate the development of immunomodulatory therapies for thyroid cancer. Overall, the dual role of inflammation in cancer has been further recognised, serving as a driver of tumour progression and a mediator of immune surveillance.</p><p id="Par22">In addition, IL-1RA, B-NGF, and M-CSF may interact in the progression of thyroid cancer to form a complex inflammatory network. For example, IL-1RA promotes inflammation through the NF-&#954;B axis and may activate B-NGF expression, which enhances cell survival and angiogenesis [<xref ref-type="bibr" rid="CR51">51</xref>]. In addition, B-NGF activates the PI3K/AKT/mTOR signalling pathway mainly through TrkA receptors, further promoting cancer cell proliferation and immune escape. On the other hand, M-CSF can regulate the tumour microenvironment through the CSF-1R receptor and affect the polarisation state of macrophages. In thyroid cancer, M-CSF may promote M1-type macrophage activation, thereby reducing IL-1RA-induced immunosuppression and forming a countervailing mechanism [<xref ref-type="bibr" rid="CR52">52</xref>]. Therefore, IL-1RA, B-NGF, and M-CSF may form a dynamic balance in the pathological process of thyroid cancer.</p><p id="Par23">Other inflammatory markers involved in this study, such as <italic toggle="yes">IL-18</italic>, were not found to have a causal relationship with the development of thyroid cancer, suggesting that thyroid cancer may be influenced by specific inflammatory pathways rather than generalised inflammatory activity. Moreover, other cytokines, although involved in inflammation, may not have a direct impact on thyroid cancer development, or their role is masked by compensatory mechanisms in the tumour microenvironment. Their potential role in thyroid cancer will be explored in future studies.</p><p id="Par24">Our study also revealed a significant role of specific SNPs in the prognosis of thyroid cancer. For instance, SNP rs71641308, located in <italic toggle="yes">B-NGF</italic>, was found to be associated with OS in thyroid cancer, whereas SNP rs11869294, located in <italic toggle="yes">IL-1RA</italic>, and SNPs rs116274860 and rs62294910, located in <italic toggle="yes">M-CSF</italic>, were associated with CSS. These factors affecting OS and CSS provide valuable insights into the genetic landscape of thyroid cancer and highlight the potential of personalised medical approaches to improve patient management and treatment strategies. Our findings suggest that individuals with genetic predispositions (e.g., rs11869294 in IL-1RA or rs71641308 in B-NGF) could benefit from enhanced surveillance, such as regular thyroid ultrasounds or serum cytokine profiling. For populations with familial thyroid cancer, integrating these SNPs into polygenic risk scores may refine early detection strategies. Furthermore, targeting IL-1RA or B-NGF with monoclonal antibodies (e.g., anakinra for IL-1RA inhibition) could synergise with existing therapies like tyrosine kinase inhibitors, potentially overcoming drug resistance in advanced cases.</p><p id="Par25">The validity of our findings was strengthened by the use of a large European cohort and SNPs, which are closely associated with inflammatory markers. Furthermore, the absence of significant heterogeneity or pleiotropy confirms the robustness of these association results. In summary, our findings offer important evidence for the causal relationship between inflammatory factors and the risk of developing thyroid cancer, not only confirming the critical role of inflammation in thyroid cancer but also providing a genetic framework for understanding individual differences in disease prognosis. These findings may help optimise screening strategies for people at high risk of thyroid cancer. For example, IL-1RA and B-NGF can be used as genetic risk markers to improve disease prediction by combining traditional thyroid cancer screening with polygenic risk score methods. In addition, M-CSF may be combined with existing immunotherapy strategies as part of targeted macrophage functional regulation to adjust the balance of inflammation in the tumour microenvironment. These findings provide new ideas for personalised intervention of thyroid cancer and deserve further research.</p><p id="Par26">However, this study has some limitations. First, this study was based on MR analyses of GWAS data from a European population, limiting generalisability to other ethnicities. Genetic variations in inflammatory pathways and environmental factors may modulate cytokine-cancer associations. Future trans-ethnic MR studies are needed to validate these findings. Second, although sensitivity analyses suggested minimal pleiotropy, residual bias from horizontal pleiotropy cannot be fully excluded. For instance, SNPs in IL-1RA may influence thyroid cancer through pathways unrelated to inflammation (e.g., metabolic regulation). Future studies using multivariable MR or colocalisation analysis could further disentangle these effects. Third, due to the complex aetiology of thyroid cancer, circulating inflammatory factors cannot fully explain its pathogenesis, and comprehensive data are needed to better guide its clinical treatment. These limitations highlight the need for further studies to validate and expand our findings.</p><p id="Par27">This study confirmed that <italic toggle="yes">IL-1RA</italic> and <italic toggle="yes">B-NGF</italic> are risk factors for thyroid cancer, whereas <italic toggle="yes">M-CSF</italic> is a protective factor. These findings lay a foundation for future research, suggesting the potential use of inflammatory factors as biomarkers or therapeutic targets. Clinical trials testing IL-1RA inhibitors or M-CSF-based therapies could translate these findings into improved patient outcomes and new directions for developing more personalised therapeutic strategies.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12672_2025_3533_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary material 1. </p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Bo Liu and Tingting Zhang have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors also would like to thank Editage (<ext-link ext-link-type="uri" xlink:href="http://www.editage.cn">www.editage.cn</ext-link>) for English language editing.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>BL and TZ contributed to conceptualization, methodology, data curation, and writing the original draft. JH and JZ contributed to conceptualization, data analysis, and graphing. WB and CN contributed to data analysis and graphing. All authors have approved the submitted version of the manuscript and agree to be accountable for all aspects of the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used in this study are derived from publicly available data sources. These data can be accessed via the following URLs/platforms: <ext-link ext-link-type="uri" xlink:href="https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x">https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par28">Not applicable. The SNP data on inflammatory factors used in this study were obtained from the Thedata.bris Research Data Repository, and the thyroid cancer GWAS data were obtained from the IEU OpenGWAS project. All datasets are publicly available, and the original studies had received approval from the appropriate ethics committees. Therefore, no further ethical approval was required for the acquisition or use of these data in this study. Not applicable. As this study only used publicly available summary-level data without any individual-level information, participant consent was not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par29">All authors reviewed and approved the final manuscript.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Tian</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global burden of thyroid cancer from 1990 to 2017</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>6</issue><fpage>e208759</fpage><pub-id pub-id-type="pmid">32589231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.8759</pub-id><pub-id pub-id-type="pmcid">PMC7320301</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Deng Y, Li H, Wang M, Li N, Tian T, Wu Y, et al. Global burden of thyroid cancer from 1990 to 2017. JAMA Netw Open. 2020;3(6):e208759.<pub-id pub-id-type="pmid">32589231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.8759</pub-id><pub-id pub-id-type="pmcid">PMC7320301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#8211;49.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janovsky</surname><given-names>CCPS</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>MS</given-names></name><name name-style="western"><surname>Novais</surname><given-names>MAP</given-names></name><name name-style="western"><surname>Maciel</surname><given-names>RMB</given-names></name><name name-style="western"><surname>Biscolla</surname><given-names>RPM</given-names></name><name name-style="western"><surname>Zucchi</surname><given-names>P</given-names></name></person-group><article-title>Thyroid cancer burden and economic impact on the Brazilian public health system</article-title><source>Arch Endocrinol Metab</source><year>2018</year><volume>62</volume><issue>5</issue><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">30462807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20945/2359-3997000000074</pub-id><pub-id pub-id-type="pmcid">PMC10118657</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Janovsky CCPS, Bittencourt MS, Novais MAP, Maciel RMB, Biscolla RPM, Zucchi P. Thyroid cancer burden and economic impact on the Brazilian public health system. Arch Endocrinol Metab. 2018;62(5):537&#8211;44.<pub-id pub-id-type="pmid">30462807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20945/2359-3997000000074</pub-id><pub-id pub-id-type="pmcid">PMC10118657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>HE</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2021</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>1</issue><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">33433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21654</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7&#8211;33.<pub-id pub-id-type="pmid">33433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>DS</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>GM</given-names></name><name name-style="western"><surname>Haugen</surname><given-names>BR</given-names></name><name name-style="western"><surname>Kloos</surname><given-names>RT</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SL</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer</article-title><source>Thyroid</source><year>2009</year><volume>19</volume><issue>11</issue><fpage>1167</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">19860577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2009.0110</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167&#8211;214.<pub-id pub-id-type="pmid">19860577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2009.0110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>YH</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Demissie</surname><given-names>K</given-names></name></person-group><article-title>Exposure to tomographic scans and cancer risks</article-title><source>JNCI Cancer Spectr.</source><year>2019</year><volume>4</volume><issue>1</issue><fpage>072</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkz072</pub-id><pub-id pub-id-type="pmcid">PMC7050152</pub-id><pub-id pub-id-type="pmid">32337490</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Shao YH, Tsai K, Kim S, Wu YJ, Demissie K. Exposure to tomographic scans and cancer risks. JNCI Cancer Spectr. 2019;4(1):072.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkz072</pub-id><pub-id pub-id-type="pmcid">PMC7050152</pub-id><pub-id pub-id-type="pmid">32337490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatch</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardis</surname><given-names>E</given-names></name></person-group><article-title>Somatic health effects of chernobyl: 30 years on</article-title><source>Eur J Epidemiol</source><year>2017</year><volume>32</volume><issue>12</issue><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">28929329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-017-0303-6</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Hatch M, Cardis E. Somatic health effects of chernobyl: 30 years on. Eur J Epidemiol. 2017;32(12):1047&#8211;54.<pub-id pub-id-type="pmid">28929329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-017-0303-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zane</surname><given-names>M</given-names></name><name name-style="western"><surname>Parello</surname><given-names>C</given-names></name><name name-style="western"><surname>Pennelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>DM</given-names></name><name name-style="western"><surname>Merigliano</surname><given-names>S</given-names></name><name name-style="western"><surname>Boscaro</surname><given-names>M</given-names></name><etal/></person-group><article-title>Estrogen and thyroid cancer is a stem affair: a preliminary study</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>26</volume><issue>85</issue><fpage>399</fpage><lpage>411</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2016.11.043</pub-id><pub-id pub-id-type="pmcid">PMC5218826</pub-id><pub-id pub-id-type="pmid">27899250</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zane M, Parello C, Pennelli G, Townsend DM, Merigliano S, Boscaro M, et al. Estrogen and thyroid cancer is a stem affair: a preliminary study. Biomed Pharmacother. 2017;26(85):399&#8211;411.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2016.11.043</pub-id><pub-id pub-id-type="pmcid">PMC5218826</pub-id><pub-id pub-id-type="pmid">27899250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Song</surname><given-names>HS</given-names></name></person-group><article-title>Persistent organic pollutants, pesticides, and the risk of thyroid cancer: systematic review and meta-analysis</article-title><source>Eur J Cancer Prev</source><year>2019</year><volume>28</volume><issue>4</issue><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">30362975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000481</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Han MA, Kim JH, Song HS. Persistent organic pollutants, pesticides, and the risk of thyroid cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2019;28(4):344&#8211;9.<pub-id pub-id-type="pmid">30362975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name></person-group><article-title>High iodine intake and central lymph node metastasis risk of papillary thyroid cancer</article-title><source>J Trace Elem Med Biol</source><year>2019</year><volume>53</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">30910201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtemb.2019.01.015</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhao H, Li H, Huang T. High iodine intake and central lymph node metastasis risk of papillary thyroid cancer. J Trace Elem Med Biol. 2019;53:16&#8211;21.<pub-id pub-id-type="pmid">30910201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtemb.2019.01.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X</given-names></name></person-group><article-title>Thyroid cancer incidence trend and association with obesity, physical activity in the United States</article-title><source>BMC Public Health</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>1333</fpage><pub-id pub-id-type="pmid">35831811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-022-13727-3</pub-id><pub-id pub-id-type="pmcid">PMC9281136</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen B, Xie Z, Duan X. Thyroid cancer incidence trend and association with obesity, physical activity in the United States. BMC Public Health. 2022;22(1):1333.<pub-id pub-id-type="pmid">35831811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-022-13727-3</pub-id><pub-id pub-id-type="pmcid">PMC9281136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coussens</surname><given-names>LM</given-names></name><name name-style="western"><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><issue>6917</issue><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature01322</pub-id><pub-id pub-id-type="pmcid">PMC2803035</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860&#8211;7.<pub-id pub-id-type="pmid">12490959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature01322</pub-id><pub-id pub-id-type="pmcid">PMC2803035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balkwill</surname><given-names>F</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow?</article-title><source>Lancet</source><year>2001</year><volume>357</volume><issue>9255</issue><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">11229684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(00)04046-0</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539&#8211;45.<pub-id pub-id-type="pmid">11229684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(00)04046-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Effects of inflammation on myopia: evidence and potential mechanisms</article-title><source>Front Immunol</source><year>2023</year><volume>2</volume><issue>14</issue><fpage>1260592</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1260592</pub-id><pub-id pub-id-type="pmcid">PMC10577208</pub-id><pub-id pub-id-type="pmid">37849748</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Xu R, Zheng J, Liu L, Zhang W. Effects of inflammation on myopia: evidence and potential mechanisms. Front Immunol. 2023;2(14):1260592.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1260592</pub-id><pub-id pub-id-type="pmcid">PMC10577208</pub-id><pub-id pub-id-type="pmid">37849748</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greten</surname><given-names>FR</given-names></name><name name-style="western"><surname>Grivennikov</surname><given-names>SI</given-names></name></person-group><article-title>Inflammation and cancer: triggers, mechanisms, and consequences</article-title><source>Immunity</source><year>2019</year><volume>51</volume><issue>1</issue><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">31315034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2019.06.025</pub-id><pub-id pub-id-type="pmcid">PMC6831096</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27&#8211;41.<pub-id pub-id-type="pmid">31315034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2019.06.025</pub-id><pub-id pub-id-type="pmcid">PMC6831096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lumachi</surname><given-names>F</given-names></name><name name-style="western"><surname>Basso</surname><given-names>SM</given-names></name><name name-style="western"><surname>Orlando</surname><given-names>R</given-names></name></person-group><article-title>Cytokines, thyroid diseases and thyroid cancer</article-title><source>Cytokine</source><year>2010</year><volume>50</volume><issue>3</issue><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">20381375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2010.03.005</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer. Cytokine. 2010;50(3):229&#8211;33.<pub-id pub-id-type="pmid">20381375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2010.03.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Relationship between serum inflammatory factor levels and differentiated thyroid carcinoma</article-title><source>Technol Cancer Res Treat</source><year>2021</year><volume>20</volume><fpage>1533033821990055</fpage><pub-id pub-id-type="pmid">33752541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1533033821990055</pub-id><pub-id pub-id-type="pmcid">PMC8093610</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhang X, Li S, Wang J, Liu F, Zhao Y. Relationship between serum inflammatory factor levels and differentiated thyroid carcinoma. Technol Cancer Res Treat. 2021;20:1533033821990055.<pub-id pub-id-type="pmid">33752541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1533033821990055</pub-id><pub-id pub-id-type="pmcid">PMC8093610</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dossus</surname><given-names>L</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>S</given-names></name><name name-style="western"><surname>Biessy</surname><given-names>C</given-names></name><name name-style="western"><surname>Navionis</surname><given-names>AS</given-names></name><name name-style="western"><surname>Travis</surname><given-names>RC</given-names></name><name name-style="western"><surname>Weiderpass</surname><given-names>E</given-names></name><etal/></person-group><article-title>Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study</article-title><source>Int J Cancer</source><year>2018</year><volume>142</volume><issue>7</issue><fpage>1332</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">29168186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31172</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Dossus L, Franceschi S, Biessy C, Navionis AS, Travis RC, Weiderpass E, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer. 2018;142(7):1332&#8211;42.<pub-id pub-id-type="pmid">29168186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31172</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>GQ</given-names></name><name name-style="western"><surname>Shen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Song</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Luo</surname><given-names>QY</given-names></name></person-group><article-title>High expression of interleukin-12A and its association with the clinicopathology and prognosis of differentiated thyroid cancer</article-title><source>Eur Thyroid J</source><year>2020</year><volume>9</volume><issue>3</issue><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">32523890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000505811</pub-id><pub-id pub-id-type="pmcid">PMC7265709</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhang GQ, Shen CT, Song HJ, Qiu ZL, Luo QY. High expression of interleukin-12A and its association with the clinicopathology and prognosis of differentiated thyroid cancer. Eur Thyroid J. 2020;9(3):139&#8211;47.<pub-id pub-id-type="pmid">32523890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000505811</pub-id><pub-id pub-id-type="pmcid">PMC7265709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name></person-group><article-title>High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer</article-title><source>BMC Endocr Disord</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>148</fpage><pub-id pub-id-type="pmid">37434155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12902-023-01407-1</pub-id><pub-id pub-id-type="pmcid">PMC10334563</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zhu L, Wang J, Hu J. High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer. BMC Endocr Disord. 2023;23(1):148.<pub-id pub-id-type="pmid">37434155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12902-023-01407-1</pub-id><pub-id pub-id-type="pmcid">PMC10334563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Expressions of IL-17 and TNF-&#945; in patients with Hashimoto's disease combined with thyroid cancer before and after surgery and their relationship with prognosis</article-title><source>Clin Transl Oncol</source><year>2020</year><volume>22</volume><issue>8</issue><fpage>1280</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">31873916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12094-019-02253-1</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zhang N, Wang Q, Tian Y, Xiong S, Li G, Xu L. Expressions of IL-17 and TNF-&#945; in patients with Hashimoto&#8217;s disease combined with thyroid cancer before and after surgery and their relationship with prognosis. Clin Transl Oncol. 2020;22(8):1280&#8211;7.<pub-id pub-id-type="pmid">31873916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12094-019-02253-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Teng</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name></person-group><article-title>Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma</article-title><source>Asia Pac J Clin Oncol</source><year>2014</year><volume>10</volume><issue>2</issue><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">23718885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajco.12075</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Li J, Teng L, Jiang H. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma. Asia Pac J Clin Oncol. 2014;10(2):149&#8211;52.<pub-id pub-id-type="pmid">23718885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajco.12075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilic</surname><given-names>I</given-names></name><name name-style="western"><surname>Guldiken</surname><given-names>S</given-names></name><name name-style="western"><surname>Sipahi</surname><given-names>T</given-names></name><name name-style="western"><surname>Palabiyik</surname><given-names>O</given-names></name><name name-style="western"><surname>Akker</surname><given-names>M</given-names></name><name name-style="western"><surname>Celik</surname><given-names>O</given-names></name><etal/></person-group><article-title>Investigation of VEGF and IL-8 gene polymorphisms in patients with differentiated thyroid cancer</article-title><source>Clin Lab</source><year>2016</year><volume>62</volume><issue>12</issue><fpage>2319</fpage><lpage>2325</lpage><pub-id pub-id-type="pmid">28164553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7754/Clin.Lab.2016.160403</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kilic I, Guldiken S, Sipahi T, Palabiyik O, Akker M, Celik O, et al. Investigation of VEGF and IL-8 gene polymorphisms in patients with differentiated thyroid cancer. Clin Lab. 2016;62(12):2319&#8211;25.<pub-id pub-id-type="pmid">28164553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7754/Clin.Lab.2016.160403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vimalraj</surname><given-names>S</given-names></name><name name-style="western"><surname>Hariprabu</surname><given-names>KNG</given-names></name><name name-style="western"><surname>Rahaman</surname><given-names>M</given-names></name><name name-style="western"><surname>Govindasami</surname><given-names>P</given-names></name><name name-style="western"><surname>Perumal</surname><given-names>K</given-names></name><name name-style="western"><surname>Sekaran</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis</article-title><source>3Biotech</source><year>2023</year><volume>13</volume><issue>10</issue><fpage>326</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13205-023-03719-4</pub-id><pub-id pub-id-type="pmcid">PMC10474002</pub-id><pub-id pub-id-type="pmid">37663750</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Vimalraj S, Hariprabu KNG, Rahaman M, Govindasami P, Perumal K, Sekaran S, et al. Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis. 3Biotech. 2023;13(10):326.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13205-023-03719-4</pub-id><pub-id pub-id-type="pmcid">PMC10474002</pub-id><pub-id pub-id-type="pmid">37663750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name></person-group><article-title>Circulating vascular endothelial growth factor and cancer risk: a bidirectional mendelian randomization</article-title><source>Front Genet</source><year>2022</year><volume>7</volume><issue>13</issue><fpage>981032</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.981032</pub-id><pub-id pub-id-type="pmcid">PMC9489904</pub-id><pub-id pub-id-type="pmid">36159967</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wu H, Ma T, Li D, He M, Wang H, Cui Y. Circulating vascular endothelial growth factor and cancer risk: a bidirectional mendelian randomization. Front Genet. 2022;7(13):981032.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.981032</pub-id><pub-id pub-id-type="pmcid">PMC9489904</pub-id><pub-id pub-id-type="pmid">36159967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>H</given-names></name><name name-style="western"><surname>Wen</surname><given-names>FY</given-names></name><name name-style="western"><surname>Xie</surname><given-names>YY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XH</given-names></name><name name-style="western"><surname>Li</surname><given-names>BX</given-names></name><name name-style="western"><surname>Peng</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Associations between depressive, anxiety, stress symptoms and elevated blood pressure: findings from the CHCN-BTH cohort study and a two-sample Mendelian randomization analysis</article-title><source>J Affect Disord</source><year>2023</year><volume>15</volume><issue>341</issue><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2023.08.086</pub-id><pub-id pub-id-type="pmid">37598715</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Qi H, Wen FY, Xie YY, Liu XH, Li BX, Peng WJ, et al. Associations between depressive, anxiety, stress symptoms and elevated blood pressure: findings from the CHCN-BTH cohort study and a two-sample Mendelian randomization analysis. J Affect Disord. 2023;15(341):176&#8211;84.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2023.08.086</pub-id><pub-id pub-id-type="pmid">37598715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name><name name-style="western"><surname>Qi</surname><given-names>G</given-names></name><name name-style="western"><surname>Grams</surname><given-names>M</given-names></name><name name-style="western"><surname>Boerwinkle</surname><given-names>E</given-names></name><name name-style="western"><surname>Snieder</surname><given-names>H</given-names></name><etal/></person-group><article-title>A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure</article-title><source>Kidney Int</source><year>2020</year><volume>98</volume><issue>3</issue><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">32454124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2020.04.044</pub-id><pub-id pub-id-type="pmcid">PMC7784392</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Yu Z, Coresh J, Qi G, Grams M, Boerwinkle E, Snieder H, et al. A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure. Kidney Int. 2020;98(3):708&#8211;16.<pub-id pub-id-type="pmid">32454124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2020.04.044</pub-id><pub-id pub-id-type="pmcid">PMC7784392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mountjoy</surname><given-names>E</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NM</given-names></name><name name-style="western"><surname>Plotnikov</surname><given-names>D</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>S</given-names></name><name name-style="western"><surname>Williams</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Education and myopia: assessing the direction of causality by mendelian randomisation</article-title><source>BMJ</source><year>2018</year><volume>6</volume><issue>361</issue><fpage>k2022</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k2022</pub-id><pub-id pub-id-type="pmcid">PMC5987847</pub-id><pub-id pub-id-type="pmid">29875094</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mountjoy E, Davies NM, Plotnikov D, Smith GD, Rodriguez S, Williams CE, et al. Education and myopia: assessing the direction of causality by mendelian randomisation. BMJ. 2018;6(361):k2022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k2022</pub-id><pub-id pub-id-type="pmcid">PMC5987847</pub-id><pub-id pub-id-type="pmid">29875094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Education and lung cancer: a Mendelian randomization study</article-title><source>Int J Epidemiol</source><year>2019</year><volume>48</volume><issue>3</issue><fpage>743</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">31219597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyz121</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhou H, Zhang Y, Liu J, Yang Y, Fang W, Hong S, et al. Education and lung cancer: a Mendelian randomization study. Int J Epidemiol. 2019;48(3):743&#8211;50.<pub-id pub-id-type="pmid">31219597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyz121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Causal relationship between inflammatory cytokines and autoimmune thyroid disease: a bidirectional two-sample Mendelian randomization analysis</article-title><source>Front Immunol</source><year>2024</year><volume>20</volume><issue>15</issue><fpage>1334772</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1334772</pub-id><pub-id pub-id-type="pmcid">PMC10989681</pub-id><pub-id pub-id-type="pmid">38571956</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yao Z, Guo F, Tan Y, Zhang Y, Geng Y, Yang G, et al. Causal relationship between inflammatory cytokines and autoimmune thyroid disease: a bidirectional two-sample Mendelian randomization analysis. Front Immunol. 2024;20(15):1334772.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1334772</pub-id><pub-id pub-id-type="pmcid">PMC10989681</pub-id><pub-id pub-id-type="pmid">38571956</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Ebrahim</surname><given-names>S</given-names></name></person-group><article-title>'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title><source>Int J Epidemiol</source><year>2003</year><volume>32</volume><issue>1</issue><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12689998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyg070</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Smith GD, Ebrahim S. &#8220;Mendelian randomization&#8221;: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1&#8211;22.<pub-id pub-id-type="pmid">12689998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyg070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>M</given-names></name></person-group><article-title>Molecular pathogenesis and mechanisms of thyroid cancer</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><issue>3</issue><fpage>184</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">23429735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3431</pub-id><pub-id pub-id-type="pmcid">PMC3791171</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184&#8211;99.<pub-id pub-id-type="pmid">23429735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3431</pub-id><pub-id pub-id-type="pmcid">PMC3791171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galdiero</surname><given-names>MR</given-names></name><name name-style="western"><surname>Varricchi</surname><given-names>G</given-names></name><name name-style="western"><surname>Loffredo</surname><given-names>S</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Marone</surname><given-names>G</given-names></name></person-group><article-title>Roles of neutrophils in cancer growth and progression</article-title><source>J Leukoc Biol</source><year>2018</year><volume>103</volume><issue>3</issue><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">29345348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3MR0717-292R</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Galdiero MR, Varricchi G, Loffredo S, Mantovani A, Marone G. Roles of neutrophils in cancer growth and progression. J Leukoc Biol. 2018;103(3):457&#8211;64.<pub-id pub-id-type="pmid">29345348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3MR0717-292R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Interleukin-1 in the pathogenesis and treatment of inflammatory diseases</article-title><source>Blood</source><year>2011</year><volume>117</volume><issue>14</issue><fpage>3720</fpage><lpage>3732</lpage><pub-id pub-id-type="pmid">21304099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-07-273417</pub-id><pub-id pub-id-type="pmcid">PMC3083294</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720&#8211;32.<pub-id pub-id-type="pmid">21304099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-07-273417</pub-id><pub-id pub-id-type="pmcid">PMC3083294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boersma</surname><given-names>B</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>P</given-names></name><name name-style="western"><surname>Bourquin</surname><given-names>C</given-names></name></person-group><article-title>The interleukin-1 cytokine family members: role in cancer pathogenesis and potential therapeutic applica-tions in cancer immunotherapy</article-title><source>Cytokine Growth Factor Rev</source><year>2021</year><volume>62</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">34620560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2021.09.004</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Boersma B, Jiskoot W, Lowe P, Bourquin C. The interleukin-1 cytokine family members: role in cancer pathogenesis and potential therapeutic applica-tions in cancer immunotherapy. Cytokine Growth Factor Rev. 2021;62:1&#8211;14.<pub-id pub-id-type="pmid">34620560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2021.09.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>SF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YM</given-names></name><name name-style="western"><surname>Chan</surname><given-names>LP</given-names></name><name name-style="western"><surname>Hung</surname><given-names>AC</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>HDH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YK</given-names></name><etal/></person-group><article-title>IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>473</fpage><pub-id pub-id-type="pmid">37461111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04343-9</pub-id><pub-id pub-id-type="pmcid">PMC10351194</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yuan SF, Wang YM, Chan LP, Hung AC, Nguyen HDH, Chen YK, et al. IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway. J Transl Med. 2023;21(1):473.<pub-id pub-id-type="pmid">37461111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04343-9</pub-id><pub-id pub-id-type="pmcid">PMC10351194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Interleukin-1 receptor antagonist inhibits matastatic potential by down-regulating CXCL12/CXCR4 signaling axis in colorectal cancer</article-title><source>Cell Commun Signal</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>122</fpage><pub-id pub-id-type="pmid">34930323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-021-00804-0</pub-id><pub-id pub-id-type="pmcid">PMC8686544</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Ma J, Liang W, Qiang Y, Li L, Du J, Pan C, et al. Interleukin-1 receptor antagonist inhibits matastatic potential by down-regulating CXCL12/CXCR4 signaling axis in colorectal cancer. Cell Commun Signal. 2021;19(1):122.<pub-id pub-id-type="pmid">34930323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-021-00804-0</pub-id><pub-id pub-id-type="pmcid">PMC8686544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nied&#378;wiecki</surname><given-names>S</given-names></name><name name-style="western"><surname>Stepie&#324;</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuzdak</surname><given-names>K</given-names></name><name name-style="western"><surname>Stepie&#324;</surname><given-names>H</given-names></name><name name-style="western"><surname>Krupi&#324;ski</surname><given-names>R</given-names></name><name name-style="western"><surname>Seehofer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Serum levels of interleukin-1 receptor antagonist (IL-1RA) in thyroid cancer patients</article-title><source>Langenbecks Arch Surg</source><year>2008</year><volume>393</volume><issue>3</issue><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">18064485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00423-007-0251-9</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Nied&#378;wiecki S, Stepie&#324; T, Kuzdak K, Stepie&#324; H, Krupi&#324;ski R, Seehofer D, et al. Serum levels of interleukin-1 receptor antagonist (IL-1RA) in thyroid cancer patients. Langenbecks Arch Surg. 2008;393(3):275&#8211;80.<pub-id pub-id-type="pmid">18064485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00423-007-0251-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voronov</surname><given-names>E</given-names></name><name name-style="western"><surname>Dotan</surname><given-names>S</given-names></name><name name-style="western"><surname>Krelin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Unique versus redundant functions of IL-1&#945; and IL-1&#946; in the tumor microenvironment</article-title><source>Front Immunol</source><year>2013</year><volume>4</volume><fpage>177</fpage><pub-id pub-id-type="pmid">23847618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2013.00177</pub-id><pub-id pub-id-type="pmcid">PMC3703603</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Voronov E, Dotan S, Krelin Y, et al. Unique versus redundant functions of IL-1&#945; and IL-1&#946; in the tumor microenvironment. Front Immunol. 2013;4:177.<pub-id pub-id-type="pmid">23847618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2013.00177</pub-id><pub-id pub-id-type="pmcid">PMC3703603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>The IL-1 family of cytokines and receptors in rheumatic diseases</article-title><source>Nat Rev Rheumatol</source><year>2019</year><volume>15</volume><issue>10</issue><fpage>612</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">31515542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-019-0277-8</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612&#8211;32.<pub-id pub-id-type="pmid">31515542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-019-0277-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czajka-Francuz</surname><given-names>P</given-names></name><name name-style="western"><surname>Prendes</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mankan</surname><given-names>A</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Pabla</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramkissoon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy</article-title><source>Front Oncol</source><year>2023</year><volume>22</volume><issue>13</issue><fpage>1200646</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1200646</pub-id><pub-id pub-id-type="pmcid">PMC10325690</pub-id><pub-id pub-id-type="pmid">37427115</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Czajka-Francuz P, Prendes MJ, Mankan A, Quintana &#193;, Pabla S, Ramkissoon S, et al. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front Oncol. 2023;22(13):1200646.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1200646</pub-id><pub-id pub-id-type="pmcid">PMC10325690</pub-id><pub-id pub-id-type="pmid">37427115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>DK</given-names></name><name name-style="western"><surname>Scharfman</surname><given-names>HE</given-names></name></person-group><article-title>Brain-derived neurotrophic factor</article-title><source>Growth Factors</source><year>2004</year><volume>22</volume><issue>3</issue><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">15518235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08977190410001723308</pub-id><pub-id pub-id-type="pmcid">PMC2504526</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004;22(3):123&#8211;31.<pub-id pub-id-type="pmid">15518235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08977190410001723308</pub-id><pub-id pub-id-type="pmcid">PMC2504526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>A</given-names></name><name name-style="western"><surname>Bindocci</surname><given-names>E</given-names></name><name name-style="western"><surname>Alleva</surname><given-names>E</given-names></name></person-group><article-title>NGF, brain and behavioral plasticity</article-title><source>Neural Plast</source><year>2012</year><volume>2012</volume><fpage>784040</fpage><pub-id pub-id-type="pmid">22474604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2012/784040</pub-id><pub-id pub-id-type="pmcid">PMC3306960</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Berry A, Bindocci E, Alleva E. NGF, brain and behavioral plasticity. Neural Plast. 2012;2012:784040.<pub-id pub-id-type="pmid">22474604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2012/784040</pub-id><pub-id pub-id-type="pmcid">PMC3306960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kermani</surname><given-names>P</given-names></name><name name-style="western"><surname>Hempstead</surname><given-names>B</given-names></name></person-group><article-title>Brain-derived neurotrophic factor: a newly described mediator of angiogenesis</article-title><source>Trends Cardiovasc Med</source><year>2007</year><volume>17</volume><issue>4</issue><fpage>140</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">17482097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcm.2007.03.002</pub-id><pub-id pub-id-type="pmcid">PMC2268985</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med. 2007;17(4):140&#8211;3.<pub-id pub-id-type="pmid">17482097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcm.2007.03.002</pub-id><pub-id pub-id-type="pmcid">PMC2268985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terracina</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferraguti</surname><given-names>G</given-names></name><name name-style="western"><surname>Tarani</surname><given-names>L</given-names></name><name name-style="western"><surname>Fanfarillo</surname><given-names>F</given-names></name><name name-style="western"><surname>Tirassa</surname><given-names>P</given-names></name><name name-style="western"><surname>Ralli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nerve growth factor and autoimmune diseases</article-title><source>Curr Issues Mol Biol</source><year>2023</year><volume>45</volume><issue>11</issue><fpage>8950</fpage><lpage>8973</lpage><pub-id pub-id-type="pmid">37998739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb45110562</pub-id><pub-id pub-id-type="pmcid">PMC10670231</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Terracina S, Ferraguti G, Tarani L, Fanfarillo F, Tirassa P, Ralli M, et al. Nerve growth factor and autoimmune diseases. Curr Issues Mol Biol. 2023;45(11):8950&#8211;73.<pub-id pub-id-type="pmid">37998739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb45110562</pub-id><pub-id pub-id-type="pmcid">PMC10670231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>ER</given-names></name><name name-style="western"><surname>Chitu</surname><given-names>V</given-names></name></person-group><article-title>CSF-1 receptor signaling in myeloid cells</article-title><source>Cold Spring Harb Perspect Biol</source><year>2014</year><volume>6</volume><issue>6</issue><fpage>a021857</fpage><pub-id pub-id-type="pmid">24890514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a021857</pub-id><pub-id pub-id-type="pmcid">PMC4031967</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6(6):a021857.<pub-id pub-id-type="pmid">24890514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a021857</pub-id><pub-id pub-id-type="pmcid">PMC4031967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ries</surname><given-names>CH</given-names></name><name name-style="western"><surname>Cannarile</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hoves</surname><given-names>S</given-names></name><name name-style="western"><surname>Benz</surname><given-names>J</given-names></name><name name-style="western"><surname>Wartha</surname><given-names>K</given-names></name><name name-style="western"><surname>Runza</surname><given-names>V</given-names></name><etal/></person-group><article-title>Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancertherapy</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><issue>6</issue><fpage>846</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">24898549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2014.05.016</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancertherapy. Cancer Cell. 2014;25(6):846&#8211;59.<pub-id pub-id-type="pmid">24898549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2014.05.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyonteck</surname><given-names>SM</given-names></name><name name-style="western"><surname>Akkari</surname><given-names>L</given-names></name><name name-style="western"><surname>Schuhmacher</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Sevenich</surname><given-names>L</given-names></name><name name-style="western"><surname>Quail</surname><given-names>DF</given-names></name><etal/></person-group><article-title>CSF-1R inhibition alters macrophage polarization and blocks glioma progression</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><issue>10</issue><fpage>1264</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">24056773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3337</pub-id><pub-id pub-id-type="pmcid">PMC3840724</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264&#8211;72.<pub-id pub-id-type="pmid">24056773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3337</pub-id><pub-id pub-id-type="pmcid">PMC3840724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukic</surname><given-names>A</given-names></name><name name-style="western"><surname>Larssen</surname><given-names>P</given-names></name><name name-style="western"><surname>Fauland</surname><given-names>A</given-names></name><name name-style="western"><surname>Samuelsson</surname><given-names>B</given-names></name><name name-style="western"><surname>Wheelock</surname><given-names>CE</given-names></name><name name-style="western"><surname>Gabrielsson</surname><given-names>S</given-names></name><etal/></person-group><article-title>GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures</article-title><source>FASEB J</source><year>2017</year><volume>31</volume><issue>10</issue><fpage>4370</fpage><lpage>4381</lpage><pub-id pub-id-type="pmid">28637652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201700319R</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Lukic A, Larssen P, Fauland A, Samuelsson B, Wheelock CE, Gabrielsson S, et al. GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures. FASEB J. 2017;31(10):4370&#8211;81.<pub-id pub-id-type="pmid">28637652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201700319R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>HM</given-names></name><name name-style="western"><surname>Oldfield</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bergin</surname><given-names>PM</given-names></name><name name-style="western"><surname>Mee</surname><given-names>EW</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>MA</given-names></name><etal/></person-group><article-title>M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia</article-title><source>J Neuroinflammation</source><year>2013</year><volume>10</volume><fpage>85</fpage><pub-id pub-id-type="pmid">23866312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-10-85</pub-id><pub-id pub-id-type="pmcid">PMC3729740</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Smith AM, Gibbons HM, Oldfield RL, Bergin PM, Mee EW, Curtis MA, et al. M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia. J Neuroinflammation. 2013;10:85.<pub-id pub-id-type="pmid">23866312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-10-85</pub-id><pub-id pub-id-type="pmcid">PMC3729740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redondo-Castro</surname><given-names>E</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro</article-title><source>Stem Cell Res Ther</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">28412968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-017-0531-4</pub-id><pub-id pub-id-type="pmcid">PMC5393041</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Redondo-Castro E, Cunningham C, Miller J, et al. Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro. Stem Cell Res Ther. 2017;8:1&#8211;11.<pub-id pub-id-type="pmid">28412968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-017-0531-4</pub-id><pub-id pub-id-type="pmcid">PMC5393041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaguin</surname><given-names>M</given-names></name><name name-style="western"><surname>Houlbert</surname><given-names>N</given-names></name><name name-style="western"><surname>Fardel</surname><given-names>O</given-names></name><etal/></person-group><article-title>Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin[j]</article-title><source>Cell Immunol</source><year>2013</year><volume>281</volume><issue>1</issue><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">23454681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellimm.2013.01.010</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Jaguin M, Houlbert N, Fardel O, et al. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin[j]. Cell Immunol. 2013;281(1):51&#8211;61.<pub-id pub-id-type="pmid">23454681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellimm.2013.01.010</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>